Cargando…
Heterotopic ossification after the use of recombinant human bone morphogenetic protein-7
AIM: To present the incidence of heterotopic ossification after the use of recombinant human bone morphogenetic protein-7 (rhBMP-7) for the treatment of nonunions. METHODS: Bone morphogenetic proteins (BMPs) promote bone formation by auto-induction. Recombinant human BMP-7 in combination with bone g...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241543/ https://www.ncbi.nlm.nih.gov/pubmed/28144577 http://dx.doi.org/10.5312/wjo.v8.i1.36 |
_version_ | 1782496203761516544 |
---|---|
author | Papanagiotou, Marianthi Dailiana, Zoe H Karachalios, Theophilos Varitimidis, Sokratis Hantes, Michael Dimakopoulos, Georgios Vlychou, Marianna Malizos, Konstantinos N |
author_facet | Papanagiotou, Marianthi Dailiana, Zoe H Karachalios, Theophilos Varitimidis, Sokratis Hantes, Michael Dimakopoulos, Georgios Vlychou, Marianna Malizos, Konstantinos N |
author_sort | Papanagiotou, Marianthi |
collection | PubMed |
description | AIM: To present the incidence of heterotopic ossification after the use of recombinant human bone morphogenetic protein-7 (rhBMP-7) for the treatment of nonunions. METHODS: Bone morphogenetic proteins (BMPs) promote bone formation by auto-induction. Recombinant human BMP-7 in combination with bone grafts was used in 84 patients for the treatment of long bone nonunions. All patients were evaluated radiographicaly for the development of heterotopic ossification during the standard assessment for the nonunion healing. In all patients (80.9%) with radiographic signs of heterotopic ossification, a CT scan was performed. Nonunion site palpation and ROM evaluation of the adjacent joints were also carried out. Factors related to the patient (age, gender), the nonunion (location, size, chronicity, number of previous procedures, infection, surrounding tissues condition) and the surgical procedure (graft and fixation type, amount of rhBMP-7) were correlated with the development of heterotopic ossification and statistical analysis with Pearsons χ(2) test was performed. RESULTS: Eighty point nine percent of the nonunions treated with rhBMP-7, healed with no need for further procedures. Heterotopic bone formation occurred in 15 of 84 patients (17.8%) and it was apparent in the routine radiological evaluation of the nonunion site, in a mean time of 5.5 mo after the rhBMP-7 application (range 3-12). The heterotopic ossification was located at the femur in 8 cases, at the tibia in 6, and at the humerus in οne patient. In 4 patients a palpable mass was present and only in one patient, with a para-articular knee nonunion treated with rhBMP-7, the size of heterotopic ossification affected the knee range of motion. All the patients with heterotopic ossification were male. Statistical analysis proved that patient’s gender was the only important factor for the development of heterotopic ossification (P = 0.007). CONCLUSION: Heterotopic ossification after the use of rhBMP-7 in nonunions was common but it did not compromise the final clinical outcome in most cases, and affected only male patients. |
format | Online Article Text |
id | pubmed-5241543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-52415432017-01-31 Heterotopic ossification after the use of recombinant human bone morphogenetic protein-7 Papanagiotou, Marianthi Dailiana, Zoe H Karachalios, Theophilos Varitimidis, Sokratis Hantes, Michael Dimakopoulos, Georgios Vlychou, Marianna Malizos, Konstantinos N World J Orthop Retrospective Study AIM: To present the incidence of heterotopic ossification after the use of recombinant human bone morphogenetic protein-7 (rhBMP-7) for the treatment of nonunions. METHODS: Bone morphogenetic proteins (BMPs) promote bone formation by auto-induction. Recombinant human BMP-7 in combination with bone grafts was used in 84 patients for the treatment of long bone nonunions. All patients were evaluated radiographicaly for the development of heterotopic ossification during the standard assessment for the nonunion healing. In all patients (80.9%) with radiographic signs of heterotopic ossification, a CT scan was performed. Nonunion site palpation and ROM evaluation of the adjacent joints were also carried out. Factors related to the patient (age, gender), the nonunion (location, size, chronicity, number of previous procedures, infection, surrounding tissues condition) and the surgical procedure (graft and fixation type, amount of rhBMP-7) were correlated with the development of heterotopic ossification and statistical analysis with Pearsons χ(2) test was performed. RESULTS: Eighty point nine percent of the nonunions treated with rhBMP-7, healed with no need for further procedures. Heterotopic bone formation occurred in 15 of 84 patients (17.8%) and it was apparent in the routine radiological evaluation of the nonunion site, in a mean time of 5.5 mo after the rhBMP-7 application (range 3-12). The heterotopic ossification was located at the femur in 8 cases, at the tibia in 6, and at the humerus in οne patient. In 4 patients a palpable mass was present and only in one patient, with a para-articular knee nonunion treated with rhBMP-7, the size of heterotopic ossification affected the knee range of motion. All the patients with heterotopic ossification were male. Statistical analysis proved that patient’s gender was the only important factor for the development of heterotopic ossification (P = 0.007). CONCLUSION: Heterotopic ossification after the use of rhBMP-7 in nonunions was common but it did not compromise the final clinical outcome in most cases, and affected only male patients. Baishideng Publishing Group Inc 2017-01-18 /pmc/articles/PMC5241543/ /pubmed/28144577 http://dx.doi.org/10.5312/wjo.v8.i1.36 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Retrospective Study Papanagiotou, Marianthi Dailiana, Zoe H Karachalios, Theophilos Varitimidis, Sokratis Hantes, Michael Dimakopoulos, Georgios Vlychou, Marianna Malizos, Konstantinos N Heterotopic ossification after the use of recombinant human bone morphogenetic protein-7 |
title | Heterotopic ossification after the use of recombinant human bone morphogenetic protein-7 |
title_full | Heterotopic ossification after the use of recombinant human bone morphogenetic protein-7 |
title_fullStr | Heterotopic ossification after the use of recombinant human bone morphogenetic protein-7 |
title_full_unstemmed | Heterotopic ossification after the use of recombinant human bone morphogenetic protein-7 |
title_short | Heterotopic ossification after the use of recombinant human bone morphogenetic protein-7 |
title_sort | heterotopic ossification after the use of recombinant human bone morphogenetic protein-7 |
topic | Retrospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241543/ https://www.ncbi.nlm.nih.gov/pubmed/28144577 http://dx.doi.org/10.5312/wjo.v8.i1.36 |
work_keys_str_mv | AT papanagiotoumarianthi heterotopicossificationaftertheuseofrecombinanthumanbonemorphogeneticprotein7 AT dailianazoeh heterotopicossificationaftertheuseofrecombinanthumanbonemorphogeneticprotein7 AT karachaliostheophilos heterotopicossificationaftertheuseofrecombinanthumanbonemorphogeneticprotein7 AT varitimidissokratis heterotopicossificationaftertheuseofrecombinanthumanbonemorphogeneticprotein7 AT hantesmichael heterotopicossificationaftertheuseofrecombinanthumanbonemorphogeneticprotein7 AT dimakopoulosgeorgios heterotopicossificationaftertheuseofrecombinanthumanbonemorphogeneticprotein7 AT vlychoumarianna heterotopicossificationaftertheuseofrecombinanthumanbonemorphogeneticprotein7 AT malizoskonstantinosn heterotopicossificationaftertheuseofrecombinanthumanbonemorphogeneticprotein7 |